ASCP: External trigeminal nerve stimulation improves treatment-resistant depression
July 6, 2015|Internal Medicine
Author and Disclosure Information
AT THE ASCP ANNUAL MEETING
Though eTNS is an investigational device in the United States, it is approved for use in Europe. U.S. randomized, double-blind, sham-controlled studies are currently testing eTNS as monotherapy in children with attention-deficit/hyperactivity disorder and as adjunctive treatment for posttraumatic stress disorder in combat veterans.
The study was funded by NeuroSigma. In addition to his management role, Dr. Cook holds stock options in the company.
On Twitter @karioakes
